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Over the last decade, one of the most pursued molecular targets 
for colorectal cancer (CRC) treatment has been EGFR, the pro-
totypical receptor tyrosine kinase (RTK) (1). However, with the 
completion of several clinical trials, it has become increasingly 
clear that targeting EGFR, either by monoclonal antibody or by 
small molecule inhibitor, has not resulted in a significant clinical 
benefit for most patients (2–6). Even dual or pan-ERBB therapeu-
tic approaches, which target EGFR and ERBB2 simultaneously, 
have achieved limited success against CRCs (7). In this study, we 
provide strong evidence that ERBB3, a pseudo-kinase member of 
the ERBB receptor family that lacks a functional kinase, may be a 
more promising target against CRC.
ERBB3 belongs to the ERBB family of RTKs, which includes 
EGFR (also known as ERBB1), ERBB2, and ERBB4 (reviewed in 
ref. 8). Unlike other ERBB receptors, ERBB3 lacks intrinsic kinase 
activity and cannot autophosphorylate due to the evolution-
ary acquisition of several changes within the kinase domain (9, 
10). Upon ligand binding, ERBB3 can be transactivated on cyto-
plasmic tyrosine residues by forming heterodimers or higher-
order oligomers with other ERBB family members (8). Tyrosine-
phosphorylated ERBB3 has the highest binding affinity for PI3K 
among the ERBB receptors because of 6 YXXM motifs that can 
directly associate with the p85 regulatory subunit of PI3K (11, 12). 
Consequently, activation of ERBB3 frequently results in strong 
activation of the PI3K/AKT signaling pathway, a critical oncogenic 
stimulus whose aberrant activity leads to apoptosis resistance in a 
wide range of cancers (13).
In contrast, the potential for ERBB3 as a target for cancer treat-
ment has been less appreciated due to its defective kinase activity. 
Nonetheless, accumulating evidence has suggested that ERBB3 
plays a critical role in cancer. Overexpression of ERBB3 often 
accompanies EGFR or ERBB2 overexpression and has been fre-
quently detected in a variety of cancers, including those of the breast 
(14), colon (15, 16), stomach (17), ovary (18), and pancreas (19). In 
ERBB2-driven cancers, ERBB3 functions as an intimate signaling 
partner that promotes the transforming potency of ERBB2, usu-
ally by activating the PI3K/AKT pathway (11, 20, 21). ERBB3 is also 
implicated in coupling EGFR to the PI3K/AKT pathway in non–
small cell lung cancers (NSCLCs) that are sensitive to EGFR inhibi-
tors such as gefitinib (22). Conversely, ERBB3-dependent activation 
of PI3K/AKT by MET leads to acquired resistance to EGFR inhibi-
tors in NSCLCs (23). It is becoming increasingly clear that in cancers 
driven by EGFR or ERBB2 signaling, ERBB3 functions as a signal-
ing partner to mediate ERBB inhibitor resistance. However, it is 
not known how ERBB3 supports cancer growth or whether ERBB3 
provides essential functions in other cancers such as those of the 
colon where EGFR and ERBB2 inhibitors have little efficacy. Using 
an engineered mouse genetic model in vivo and human cell line in 
vitro, we provide evidence that ERBB3 is essential for CRC growth 
by preventing apoptosis through ERBB3-ERBB4 heterodimers.
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Results
Generation and validation of a conditional Erbb3 allele. Homologous 
recombination was used to generate an Erbb3-null allele (Erbb3tm1Dwt1) 
by deletion of exon 2 in order to verify that a conditional allele tar-
geting the same exon would function as a null allele (Figure 1A). 
Eight targeted ES cell clones were obtained from 194 colonies 
screened by Southern blot analysis (Supplemental Figure 1A; sup-
plemental material available online with this article; doi:10.1172/
JCI36435DS1). The Neo selection cassette was removed by transient 
Cre expression, and colonies with complete excision were identified 
by PCR. Sequencing of 4 independent PCR-positive clones showed 
that Cre-mediated excision occurred correctly. One clone with the 
Erbb3tm1Dwt1 (also called Erbb3–) null allele was used to generate 
chimeric mice that successfully passed the null allele through the 
germline. The allele was subsequently kept coisogenic on the 129S6/
SvEvTAC background or made congenic on a C57BL/6J (B6) back-
ground through 10 backcrosses. Intercrosses of heterozygous mice 
on either background resulted in no Erbb3– homozygous mice at 
3 weeks of age. Analysis of embryos at 13–15 days post coitum showed 
that 52% (17 of 33) of Erbb3– homozygous embryos were dead, simi-
lar to previous analyses of Erbb3 nullizygous embryos (24, 25), verify-
ing that deletion of exon 2 from Erbb3 results in a null allele.
To generate the conditional Erbb3tm1Dwt2 allele (also called Erbb3f ), 
we used homologous recombination to flank exon 2 with loxP 
sites (Figure 1B). Five targeted ES cell clones were obtained from 
242 colonies analyzed by Southern blot analysis (Supplemental 
Figure 1B). After removing the Neo selection cassette in targeted 
clones by transient expression of Cre, we used one targeted ES cell 
clone to generate chimeric mice, which successfully transmitted 
the conditional Erbb3f allele through the germline. Intercrossing 
Erbb3f/+ with Erbb3+/– mice resulted in normal Mendelian ratios of 
Erbb3f/– mice at 3 weeks of age, and these mice were normal and 
fertile, indicating that the Erbb3f allele functions as a wild-type 
allele (data not shown).
RT-PCR analysis using RNA from the small intestine of Erbb3+/– 
mice resulted in a 517-bp RT-PCR product for the wild-type allele 
and a 365-bp RT-PCR product for the Erbb3– allele due to splicing 
from exon 1 to 3 creating a nonsense mutation. RT-PCR analysis 
using RNA from the small intestine of Erbb3f/– mice showed the 
same pattern, indicating that the addition of loxP sites does not 
alter RNA splicing (Supplemental Figure 1, C and D).
The Erbb3f allele was verified to function as a null allele after 
Cre-mediated excision of exon 2 as predicted from the Erbb3– 
allele. Homozygous Erbb3-null embryos die at mid-gestation 
due to defects in the heart, which has underdeveloped endocar-
dial cushions and Schwann cells (23–25). Since developmental 
defects of nullizygous mutants are known to sometimes occur 
secondary to placental defects (26), Erbb3+/– mice were crossed 
with Sox2-CreTg/+ mice, which express Cre in epiblast-derived tis-
sues (27). Erbb3+/–Sox2-CreTg/+ mice were then crossed with Erbb3f/+ 
mice and the survival of Erbb3f/–Sox2-CreTg/+ mice was evaluated. 
PCR resulted in a 193-bp PCR product specific for the null allele 
(Erbb3fd) derived from Cre-mediated excision of exon 2 from Erbb3f. 
Among the 50 pups resulting from the cross, none were genotyped 
as Erbb3f/–Sox2-CreTg/+ (data not shown). This result demonstrates 
that embryonic lethality results from loss of Erbb3 in the embryo 
proper and also indicates that the Erbb3fd allele functions similarly 
to the Erbb3– null allele.
Normal cell proliferation and apoptosis in ERBB3-deficient intestinal 
epithelium. Semiquantitative RT-PCR analysis comparing relative 
Erbb3 mRNA levels across various tissues revealed that relatively 
high levels of Erbb3 transcripts are present throughout the gastro-
intestinal tract, including the stomach, small intestine, and colon 
(Supplemental Figure 2). To determine whether Erbb3 is required 
for normal intestinal homeostasis, we crossed Erbb3f/+ mice with 
Vil-CreTg/+ mice, which express Cre throughout the epithelium 
of the small intestine and colon and in the proximal tubule of 
the kidneys (28). Mice with intestine-specific deletion of Erbb3 
(Erbb3f/fVil-CreTg/+ or Erbb3f/–Vil-CreTg/+, also called Erbb3 mutant 
mice) were compared with control littermates (Erbb3f/+Vil-CreTg/+, 
Erbb3+/–Vil-CreTg/+, or Erbb3f/fVil-Cre+/+). PCR genotyping using ear 
or epithelial tissues scraped from the surface of the small intestine 
and colon revealed that the Erbb3fd allele was generated only in the 
small intestine and the colon (Figure 1C). Western blot analysis 
revealed that ERBB3 expression was completely absent in the epi-
thelial layer of the intestine harvested from Erbb3 mutant mice 
(Figure 1D); specific ablation of ERBB3 expression from epithe-
lial cells was verified by immunohistochemistry (Figure 1E and 
Supplemental Figure 3). Interestingly, alterations in the relative 
levels of ERBB receptors were observed in the intestinal epithe-
lium of Erbb3 mutant mice, with slightly higher levels of ERBB2 
and almost complete absence of ERBB4. No changes in transcript 
levels as measured by RT-PCR were observed for any Erbb gene, 
suggesting that deregulated ERBB levels occur posttranscription-
ally (data not shown).
To address the effect of intestinal epithelium–specific Erbb3 dele-
tion on cell proliferation, we compared Erbb3 mutant mice with 
controls after BrdU injection. The number of BrdU-positive cells 
per crypt in the colon was not significantly different between the 
two groups (Figure 2, A and B). Apoptosis was quantified using 
the TUNEL assay and also showed no significant alteration in the 
colons of Erbb3 mutant mice compared with controls (Figure 2, A 
and C). The numbers of BrdU- or TUNEL-positive cells was also the 
same in the small intestine in the two groups (data not shown).
Signaling via PI3K is unique to ERBB3 because of its six p85 sub-
unit binding sites (29, 30). Upon binding of PI3K to ERBB3, phos-
phatidylinositol-3,4,5-triphophate (PIP3) is produced to recruit sig-
naling molecules containing pleckstrin homology (PH) domains 
such as the protein serine-threonine kinases AKT1 and PDK1 (31). 
The relative level of phospho-PDK1 and phospho-AKT1 in intesti-
nal epithelia was similar in Erbb3 mutant and control mice (Figure 
2D). Phospho-RPS6KB1, which is downstream of AKT1, was also 
expressed at similar levels in intestinal samples from the groups, as 
was phospho-MAPK1/MAPK3 and phosphorylated stress-induced 
protein kinase/JNK (phospho-SAPK/JNK). These results show that 
overall downstream signaling in normal intestinal epithelia is not 
altered by deletion of Erbb3, consistent with a lack of alteration in 
cell proliferation or cell death.
ERBB3 is required to maintain intestinal homeostasis. The impor-
tance of ERBB3 for maintaining intestinal homeostasis in the 
context of damage was evaluated by measuring susceptibility to 
intestinal injury caused by dextran sodium sulfate (DSS). Analy-
sis of body weight loss over 8 days of DSS treatment revealed a 
statistically significant difference between Erbb3 mutant mice 
and controls (Figure 3A). After treatment, colon histology was 
examined. There were statistically significant differences in his-
tological scores between Erbb3 mutant mice and controls (Figure 
3B). Mild lesions revealed loss of mucus cells, glandular hyperpla-
sia, and increased leukocyte levels in the lamina propria. Severe 
lesions had a complete loss of glandular epithelium, accompanied 
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Figure 1
Targeting the Erbb3 locus. (A) Targeted ES cells containing TK-Neo flanked by lox71 (open symbols) and loxP (filled symbols) were transfected 
with a Cre expression vector to generate the Erbb3 null allele without exon 2. A fragment upstream of 5′ homology was used as a probe for 
Southern blots. The primers (arrowheads) were used for PCR to discern the Erbb3 wild-type and null alleles. (B) Targeted ES cells containing 
exon 2 flanked with lox71 and loxP were transfected with a Cre expression vector to generate the Erbb3f conditional allele. The Erbb3fd allele, 
generated by Cre-mediated excision of exon 2 in the Erbb3f allele, was induced by breeding with tissue-specific Cre transgenic lines. (C) PCR 
genotyping with DNA from ear (Ea), colon (Co), and jejunum (Sij) of Erbb3f mice crossed to Vil-Cre mice. Lane M, 1-kb ladder; Tg, Vil-Cre 
transgenic mouse. PCR produces a 488-bp product specific for the Erbb3f allele (f), a 354-bp product for the wild-type Erbb3 allele (+), a 235-bp 
product for the Erbb3 null allele (–), a 193-bp product for the Erbb3fd allele (fd), and a 278-bp product for the Vil-Cre transgene. (D) Tissue 
extracts from the epithelium of jejunum analyzed by Western blotting with anti-ERBB3, anti-EGFR, anti-ERBB2, and anti-ERBB4 antibodies. (E) 
Immunofluorescence staining for ERBB3. Representative intestinal sections with wild-type levels of ERBB3 (top) and intestine-specific deletion 
of ERBB3 (bottom). Staining is shown individually and merged for ERBB3 and the epithelial marker E-cadherin (CDH1). There is background 
nuclear staining in the ERBB3 mutant tissue. DAPI staining shows locations of nuclei. Original magnification, ×200.
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by collapse of the denuded lamina propria, submucosal edema, 
fibrinoid necrosis of lamina propria vessels, and infiltration of 
neutrophils and plasma cells (Figure 3C).
Growth of ApcMin tumors requires ERBB3. Wild-type and Erbb3 
mutant genotypes were combined with ApcMin to evaluate the 
importance of ERBB3 signaling during intestinal tumorigenesis. At 
3 months of age, all ApcMin mice examined developed visible tumors 
(>0.3 mm in diameter) in the small intestine regardless of Erbb3 
genotype. However, the number of macroadenomas in the small 
intestine of ApcMin, Erbb3 mutant mice was reduced dramatically 
compared with that in ApcMin controls (10.6 ± 6.8 vs. 91.9 ± 76.0; 
Figure 4A). This ERBB3-dependent reduction in the number of 
small intestine tumors was observed in all regions of the small 
intestine, with the greatest effect in the duodenum and jejunum 
(Supplemental Figure 4). Whereas half of the ApcMin control mice 
developed at least 1 colon tumor, no colon tumors were observed 
in any of the ApcMin, Erbb3 mutant mice (Figure 4B).
Tumors forming in ApcMin, Erbb3 mutant mice, which lack intesti-
nal epithelial expression of ERBB3, were significantly smaller than 
the tumors that developed in ApcMin control mice (size [mean ± SEM, 
0.62 ± 0.48 mm vs. 0.94 ± 0.45 mm; Figure 4C), suggesting that 
ERBB3 signaling is essential for tumor growth. While only 60% of the 
tumors in age-matched control mice were small, 87.0% of the tumors 
in ApcMin, Erbb3 mutant mice were less than 1 mm in diameter (Figure 
4D). Similarly, the fraction of tumors between 1 and 2 mm in diam-
eter was also reduced in ApcMin, Erbb3 mutant mice compared with 
controls (9.3% and 38.2%, respectively). Histological analysis of size-
matched tumors did not reveal any overt morphological differences 
related to Erbb3 genotype (data not shown).
Loss of ERBB3 results in elevated caspase 3–mediated apoptosis in tumors. 
We measured the level of proliferation and apoptosis within ApcMin 
tumors to determine the cellular mechanism responsible for 
reduced tumor size in the absence of ERBB3. Immunohistochemical 
staining with the proliferation marker Ki-67 showed that prolifer-
Figure 2
Analysis of intestine-specific Erbb3-knockout mice. (A) Colon sections from mice injected with BrdU for 2 hours before sacrifice were stained with 
hematoxylin and eosin Y (H&E), immunostained with anti-BrdU antibody, and assayed for TUNEL-positive cells. Original magnification, ×200. 
(B) Number of BrdU stained cells per crypt in Erbb3 wild-type, heterozygous Erbb3+/–, and Erbb3 mutant mice. (C) Number of TUNEL-positive 
cells per crypt in wild-type, heterozygous, and Erbb3 mutant mice. (D) Tissue extract prepared from the epithelium of the jejunum from various 
Erbb3 genotypes analyzed by Western blotting for the indicated markers. Tg, Vil-CreTg/+. Error bars indicate SEM.
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ating cells in normal intestinal epithelium are confined to the pro-
liferative zone of the crypts. Irrespective of Erbb3 genotype, Ki-67– 
positive cells were expanded in ApcMin tumors as identified by 
colabeling with nuclear CTNNB1 (Figure 5, A–F). The prolifera-
tion index, determined by the ratio of Ki-67 to DAPI staining, was 
not significantly different based on Erbb3 genotype (Figure 5K). In 
contrast, apoptosis in tumors measured by TUNEL staining was 
significantly different based on Erbb3 genotype (Figure 5, G–J). An 
increase in the number of TUNEL-positive cells was observed in 
tumors from ApcMin, Erbb3 mutant mice compared with tumors 
from ApcMin control mice (Figure 5L), showing that loss of ERBB3 
leads to elevated cell death via apoptosis specifically in intestinal 
tumor cells but not in normal intestinal epithelium.
To investigate the molecular mechanism of ERBB3-dependent 
tumor cell survival, we examined downstream signaling events in 
individual size-matched tumors from ApcMin, Erbb3 mutant and ApcMin 
control mice (Figure 6A); we analyzed individual tumors from ApcMin, 
Erbb3 mutant mice to verify lack of ERBB3 expression. The relative 
phosphorylated/total protein levels of signal mediators downstream 
of PI3K were lower in tumors from ApcMin, Erbb3 mutant mice com-
pared with ApcMin control mice when normalized using ACTB levels 
to non-tumor epithelium from the same mouse (Figure 6B).
Because there were significant differences in apoptotic indices 
between control and ERBB3-deficient tumors using the TUNEL 
assay, individual tumors were analyzed for the relative levels of 
cleaved caspase-3 (CASP3) and poly(ADP-ribose) polymerase 
(PARP) (Figure 6A). Total CASP3 levels were decreased in ApcMin 
tumors compared with normal epithelium, as reported previ-
ously (32). Consistent with the higher apoptotic index observed 
in tumors from ApcMin, Erbb3 mutant mice compared with ApcMin 
control mice, the level of cleaved CASP3 was higher in ERBB3-defi-
cient tumors, as was the level of cleaved PARP (Figure 6C).
To validate these results, we performed immunohistochemistry for 
phospho-RPS6 (Figure 6D). Strong cytoplasmic immunoreactivity 
was observed in tumors from ApcMin control mice as well as in the 
nontransformed normal epithelial cells surrounding tumors. How-
ever, in size-matched tumors from ApcMin, Erbb3 mutant mice, phos-
pho-RPS6 immunoreactivity was markedly reduced, consistent with 
the reduced phospho-RPS6 levels observed by Western blot analysis.
Loss of ERBB3 or ERBB4 causes apoptosis in human colon cancer cells. 
As the disappearance of ERBB4 protein in ERBB3-deficient intesti-
nal epithelium suggests that elevated apoptosis may be due to loss 
of ERBB3-ERBB4 heterodimers, the dependency on both ERBB3 
and ERBB4 was tested using HCT116 human colon cancer cells, 
a KRAS mutant line that is relatively resistant to EGFR inhibition 
(33). HCT116 cell numbers were significantly attenuated by siRNA 
knockdown of either ERBB3 (siRNA B3-3) or ERBB4 (siRNA B4-2) 
(Figure 7A), which was caused by an increase in apoptosis as deter-
mined by TUNEL staining (Figure 7, B and C). Although overall 
cell numbers at the time point measured was not affected by siRNA 
B3-1, there was a marked increase in cell blebbing compared with 
controls, which was probably due to apoptosis (Figure 7C). There 
was no effect on cell numbers or apoptosis using siRNA B4-1 or a 
scrambled siRNA control.
To determine whether the level of human ERBB4 is dependent 
on ERBB3 as observed in mice, the expression of all ERBB recep-
tors was analyzed in ERBB3 and ERBB4 siRNA–treated HCT116 
cells (Figure 7D). The two siRNAs for ERBB3 showed near com-
plete knockdown of ERBB3 expression. Knockdown of ERBB3 
also resulted in a marked reduction in ERBB4 levels similar to 
that observed in the Erbb3 mutant mouse intestinal tissue. Only 
1 siRNA for ERBB4 (B4-2) reduced ERBB4 levels, which had only 
a modest effect on ERBB3 expression. No effect was observed on 
EGFR or ERBB2 after ERBB3 or ERBB4 knockdown. The level of 
expression of ERBB3 and ERBB4 after siRNA knockdown was con-
sistent with their effects on cell numbers and apoptosis.
The activity of several signal mediators downstream of ERBB3 
was also reduced in HCT116 cells treated with ERBB3 or ERBB4 
Figure 3
Response of mice with intestine-specific Erbb3 deletion to DSS treatment. (A) Body weights over time expressed as a percentage of the weight 
on the day of first exposure to DSS. Data are presented as mean ± SD. (B) Scoring of histological damage as described in Methods. Each dot 
represents an individual Erbb3 wild-type (filled circles), Erbb3 heterozygous (gray circles) or Erbb3 mutant (open circles) mouse. Histological 
scores were significantly different between Erbb3 mutant and either wild-type or heterozygous mice. Horizontal bars represent means. (C) His-
tological response of colons from Erbb3 mutant mice to DSS exposure. Top: Low-magnification view (original magnification, ×40) of colon cross 
section. Bottom: High-magnification view (×200) of inflammation *P < 0.05, unpaired Student’s t test.
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siRNA (Figure 7D). Knockdown of ERBB3 by B3-3 resulted in the 
largest reduction in phospho-AKT and phospho-RPS6 levels. Cells 
lines with ERBB3 or ERBB4 knockdown all had elevated PARP 
cleavage, consistent with elevated apoptosis. Similar to the in vivo 
results using mice and consistent with the KRAS mutant status of 
HCT116, there was no effect on MAPK activity, which is typically 
associated with cell proliferation. Overall, these results suggest 
that ERBB3-ERBB4 heterodimer–dependent AKT pathway activa-
tion may be required to prevent colon cancer cell apoptosis.
Discussion
Pseudo-kinases such as ERBB3 are emerging as crucial regulators 
of diverse cellular functions, despite lacking the ability to directly 
phosphorylate substrates (34). Using mice with an intestinal epi-
thelium–specific Erbb3 deletion, we revealed a damage response–
specific role for Erbb3 in intestinal biology. We found that Erbb3 
is not essential for normal intestinal homeostasis, which is sup-
ported by normal levels of downstream signal mediators associ-
ated with ERBB3. Unlike in normal epithelium, we found that 
Erbb3 is essential to protect against intestinal damage caused by 
chemically induced colitis.
Although ERBB3 lacks intrinsic kinase activity, circumstantial 
evidence has accumulated suggesting that activation of ERBB3-
dependent pathways can modulate cancer phenotypes (17, 35). 
Generation of Erbb3 mutant mice allowed us to examine intestinal 
tumor development in epithelium deficient for ERBB3 activity. In 
the ApcMin mouse model, ERBB3 epithelial deficiency has a pro-
found effect on tumor number, reducing it by 90%. Furthermore, 
there was a complete absence of tumors in the colons of ApcMin 
lacking epithelial ERBB3. Previous work by our group showed 
that genetic or biochemical blockade of EGFR activity results 
in a similarly reduced tumor number in the ApcMin model. How-
ever, the residual tumors present in the context of EGFR inhibi-
tion are indistinguishable in size from those arising in mice with 
wild-type Egfr (33, 36). Unlike blocking of EGFR signaling, ERBB3 
deficiency in mice results in a significant reduction in the average 
size of the remaining tumors. Our results, albeit more striking, are 
similar to the concomitant reduction in tumor number and size 
by treatment with EGFR-related protein (ERRB), which is thought 
to function as a pan-ERBB inhibitor (37), suggesting that ERBB3 
may be the important target for ERRB.
While the extent of proliferation in ApcMin tumors from Erbb3 
mutant mice is comparable to that in animals with wild-type Erbb3, 
a greater number of apoptotic cells was detected in the ERBB3-defi-
cient tumors from ApcMin mice, demonstrating an important role for 
ERBB3 in tumor cell survival. Strikingly, this was specific to tumors, 
as normal epithelium remained unaffected. Consistent with a lack 
of effect on cell proliferation, ERBB3-deficient tumors have normal 
Figure 4
Effect of intestine-specific Erbb3 deficiency on ApcMin tumor development. (A) Intestinal macroadenoma multiplicity in ApcMin mice. Tumor num-
bers in small intestines of ApcMin mice counted under a dissecting microscope. Each dot represents the total number of tumors (>0.3 mm) from 
single 3-month-old control (n = 16) or Erbb3 mutant (n = 14) mice. Horizontal lines indicate mean tumor number. (B) Colonic tumor multiplicity in 
ApcMin mice. Each dot represents the total number of tumors in the colon from a single mouse. (C) Intestinal macroadenoma size analysis. Each 
dot represents the tumor size of individual tumor. (D) Size range of tumors in ApcMin mice. Black bars indicate mean values for ApcMin control 
mice, and white bars indicate mean values for ApcMin Erbb3 mutant mice. †P < 0.00001; ‡P < 0.0005; **P < 0.001; *P < 0.05; Wilcoxon rank-sum 
test. Horizontal bars in A–C represent means.
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levels of MAPK1/MAPK3 activation, which is the predominant epi-
thelial mitogenic signal. In contrast, the level of phosphorylated 
RPS6 is significantly reduced in ERBB3-deficient tumors. RPS6 is 
phosphorylated by RPS6KB1, a major target of FRAP1 (mammalian 
target of rapamycin [mTOR]) that is downstream of PI3K and AKT. 
The PI3K/AKT/FRAP1/RPS6 pathway is associated with cell surviv-
al through regulation of cell-cycle arrest and apoptosis (38). Consid-
ering that numerous growth factors are expressed in the intestinal 
epithelium, creating redundancy in the activation of RTKs (39), it 
is surprising that lack of ERBB3 leads to alterations in downstream 
signaling mediators only upon tumor development.
Our results show that ERBB3 signaling contributes to tumor 
growth by activating the PI3K/AKT/FRAP1/RPS6 pathway, result-
ing in prevention of CASP3-mediated apoptosis. Since previous 
studies showed that genetic or pharmacologic blockade of EGFR 
leads to a reduction in tumor number but not tumor size (33), we pos-
tulate that ERBB3 has a dual role during tumorigenesis (Figure 8). 
Although we cannot exclude the possibility of essential parallel 
EGFR and ERBB3 pathways, we propose a model consistent with 
known ERBB interactions whereby the primary pathway support-
ing tumor survival in the ApcMin model is through an EGFR-ERBB3 
heterodimeric complex that activates both mitogenic and anti-
apoptotic signaling pathways. This complex would be blocked by 
the absence of either EGFR or ERBB3, which explains the equiva-
lent reduction in tumor number observed in the absence of either 
receptor. Though EGFR can activate PI3K/AKT through associa-
tion with the adaptor protein GAB1 in ApcMin tumors (40), our 
model predicts that activation of PI3K/AKT by EGFR-ERBB3 het-
erodimers is a major mechanism supporting colon tumor growth. 
This is consistent with previous studies showing that ERBB3 can 
couple EGFR to PI3K/AKT (11, 12), leading to an antiapoptotic 
signal from EGFR.
Our proposed model also predicts that a second pathway, which 
is EGFR independent but ERBB3 dependent, exists to support 
survival of a minority of tumors. Cancer survival may be mediated 
by an ERBB3-ERBB4 heterodimeric complex, since loss of ERBB3 
results in a concomitant loss of ERBB4 in both mice and humans 
and loss of ERBB4 in human colon cancer cells leads to elevated 
apoptosis. This model is consistent with data showing that with 
EGFR blockade, the size of remaining tumors in unaffected, while 
in the absence of ERBB3, the size of remaining tumors is reduced 
significantly. Loss of EGFR would not affect the secondary pathway, 
and the tumors arising in the absence of EGFR would not be growth 
impaired, which is consistent with our previous observations (33). 
Figure 5
Proliferation and apoptosis in 
intestinal tumors. (A and B) DAPI 
staining, (C and D) CTNNB1 
immunostaining, (E and F) Ki-67 
immunostaining, and (G and H) 
DAPI staining with (I and J) matched 
TUNEL staining of size-matched 
intestinal tumors from 3-month-old 
control (ApcMinErbb3+/–Vil-CreTg/+ 
and ApcMinErbb3f/–Vil-Cre+/+) and 
Erbb3 mutant (ApcMinErbb3f/–Vil-
CreTg/+) mice. Original magnifica-
tion, ×200. (K) Proliferation index as 
represented by the ratio of Ki-67– 
positive cells to DAPI-stained cells 
in ApcMin tumors. (L) Graph of 
apoptosis index as represented 
by the number of TUNEL-posi-
tive cells per 100 cells in tumors. 
*P < 0.05, Student’s t test. Error 
bars represent SEM.
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Finally, this model predicts that loss of ERBB3 would not prevent 
tumors from developing using the secondary pathway. Rather, loss 
of ERBB3 results in reduced tumor growth rates caused by elevated 
apoptosis in the absence of efficient PI3K/AKT signaling to RPS6.
The therapeutic implications of these results are that pharmaceu-
tical blockade of ERBB3 may be efficacious against colon cancer. 
However, there are important differences between pharmaceutical 
blockade and the genetic ablation reported here, which may result 
in different responses in the clinic. Genetic blockade results in 
the loss of ERBB3 and subsequently ERBB4 from the cell surface, 
while pharmaceutical inhibition of cell surface receptors generally 
does not result in receptor loss. Rather, pharmaceutical block-
ade typically inhibits activity of targeted receptors while retain-
ing their expression. If colon cancer survival is dependent upon 
ERBB4, and expression of ERBB4 is not reduced unless ERBB3 
expression is eliminated, then pharmaceutical blockade of ERBB3 
may not result in loss of ERBB4 expression. Retention of ERBB4 
expression during ERBB3 pharmaceutical blockade may result in 
a lack of cancer inhibition, in contrast to the present results from 
genetic studies. This result may be overcome by pharmaceutical 
blockade of ERBB4.
In this study, we observed a profound ERBB3-dependent reduc-
tion in tumor multiplicity and size. The robust tumor-promoting 
activity of ERBB3 results from its unique link to PI3K/AKT and its 
downstream effectors FRAP1 and RPS6, leading to inhibition of 
the proapoptotic mediators CASP3 and PARP. Since kinase-dead 
ERBB3 must partner with another ERBB to function, lack of ERBB3 
would abolish all heterodimers containing ERBB3 simultaneously 
and abolish efficient signaling to the PI3K/AKT pathway, which 
may contribute to the pronounced antitumor effects in the absence 
of ERBB3. Consequently, targeting heterodimeric complexes formed 
with ERBB3 is predicted to be more efficacious than targeting other 
Figure 6
ERBB3 pathway analysis in ApcMin tumors. (A) Tissue extract from individual tumors and normal epithelia analyzed by Western blotting for 
ERBB and downstream signal mediators. N, normal epithelium; T, tumors. Signals were quantified by densitometry. (B) Normalized ratios 
(phosphorylated/total) of activities for ERBB3 signal mediators. (C) Relative apoptosis levels in each tumor as a function of normal epithelium 
were determined from the normalized ratios of cleaved to total forms of CASP3 and total PARP. Black bars, mean values for tumors from control 
mice (Erbb3f/f; n = 4); white bars, mean values for tumors from Erbb3 mutant mice (Erbb3f/fVil-CreTg; n = 4). (D) Immunostaining for phospho-
RPS6 in intestinal tumors from 3-month-old ApcMin, control (Erbb3+/–Vil-CreTg) and Erbb3 mutant (Erbb3f/–Vil-CreTg) mice. Original magnification, 
×200. *P < 0.05, unpaired Student’s t test. Error bars represent SEM.
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ERBB receptors. Our findings also suggest that inhibition of the 
PI3K/AKT pathway, the major downstream effector of ERBB3-
dependent signaling, may be effective in treating intestinal cancers 
when used in combination with EGFR inhibitors.
Methods
Generation of Erbb3 null allele. Genomic DNA including Erbb3 was ampli-
fied from a GenomeWalker library (Clontech) with sense and antisense 
primers of exon 2 based on a partial Erbb3 cDNA sequence of extracellular 
domain (GenBank accession number AF059175). The resulting genomic 
DNA fragments of upstream (2.2 kb from a PvuII GenomeWalker library) 
and downstream (3.6 kb from a DraI GenomeWalker library) of exon 2 
were confirmed by sequencing. To construct the targeting vector, a TK-
Neo fusion cassette, pTNFUS69Py (41), was flanked with lox71 and loxP 
before PCR amplification of the 5′ homology region (2 kb) and 3′ homol-
ogy region (3.5 kb) using 129S6/SvEvTAC genomic DNA and subcloning 
the floxed TK-Neo fusion cassette (Figure 1A). Homologous recombina-
tion in TL-1 ES cells was performed as described previously (42). Clones 
were screened for accurate homologous recombination by Southern blot 
hybridization using DNA isolated from ES cell clones that was digested 
with BamHI, electrophoretically separated on 0.8% agarose gel, and trans-
ferred to a Nylon membrane (Schleicher & Schuell). The membrane was 
screened with an 0.6-kb probe derived from an EcoRV and PvuII DNA frag-
ment upstream of the 5′ homology region. To remove the TK-Neo cassette 
Figure 7
Effect of ERBB3 and ERBB4 knockdown on HCT116 cells. (A) Cell proliferation relative to transfection reagent control only. Two negative controls, 
transfection reagent only (C1) and scrambled siRNA duplex (C2), are shown with ERBB3-siRNA2 (B3-1), ERBB3-siRNA3 (B3-3), ERBB4-siRNA1 
(B4-1), and ERBB4-siRNA2 (B4-2). Bars indicate means, with standard errors of 2 independent experiments; each experiment was performed in 
quadruplicate. *P < 0.01, paired Student’s t test, 2-tailed compared with C1 or C2. (B) TUNEL and DAPI staining after siRNA transfection. Original 
magnification, ×200. (C) Apoptosis index as represented by the percentage of TUNEL-positive cells relative to DAPI-stained cells. More than 400 
cells were counted from at least 4 different microscopic fields. Two independent experiments showed similar results. Bars represent mean and 
SEM. *P < 0.01, unpaired Student’s t test, 1-tailed compared with C1. (D) Western blot of ERBB3 and downstream signal mediators.
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in the targeted allele, the targeted ES cell were electroporated with 10 μg 
pCreEGFP that expresses a Cre-EGFP fusion protein under the human 
cytomegalovirus immediate early promoter. ES cells were passed once, 
two days after electroporation, and individual ES cell clones picked at 
two days after passaging. DNA isolated from ES cell clones was digested 
with BamHI and analyzed by Southern blotting as described above. Since 
the BamHI fragment of the endogenous and excised alleles was similar 
in size by Southern blot analysis, PCR was performed with mErbb3-S1, 
5′-TCCAGCGTGGAAAAGTTCAC-3′ and mErbb3-AS1, 5′-AAGCCTTCTC-
TATGGAAAGTG-3′ primers. PCR products were subcloned to TOPO2.1 
vector (Invitrogen), and Cre-mediated excision was further confirmed by 
sequencing. Chimeric mice were generated by morula aggregation with 
CD-1–derived morulas before implantation into surrogate dams (42). 
Selected chimeras were bred to identify germline transmission of the tar-
geted allele. Subsequent generations of mice carrying the Erbb3 null allele 
were maintained isogenic on 129S6/SvEvTAC and, after 10 generations of 
backcrossing, congenic on B6 genetic backgrounds. Genotypes were deter-
mined by PCR with mErbb3-S1 and mErbb3-AS1 primers.
Generation of Erbb3 conditional allele. An EcoRV and PvuII fragment 
upstream of the 5′ homology region of the Erbb3 targeting vector described 
above was used as a probe to screen a 129S6/SvEvTAC BAC library (RPCI-22; 
Roswell Park Cancer Institute). Genomic DNA from one BAC clone, 
65B22, was amplified with PCR to generate 5′ homology (3.9-kb) and 
3′ homology (3.5-kb) regions, and a fragment containing exon 2 flanked 
lox71 sites. All 3 fragments were inserted into a Pgk-Neo cassette flanked 
by loxP sites to generate the conditional targeting vector (Figure 1B). All 
ligation junctions were verified by DNA sequencing. Gene targeting was 
done as described above. DNA isolated from ES cell clones was screened 
with an 0.65-kb probe derived from an EcoRI-to-PvuII genomic DNA frag-
ment upstream of the 5′ homologous arm of the targeting construct. 
After removal of the Pgk-Neo cassette in the targeted allele as described 
above, the floxed allele was further screened by PCR with mErbb3-S1 and 
mErbb3-AS1. Chimeric mice were generated by morula aggregation with 
CD-1–derived morula and implanted into surrogate dams (42). Selected 
chimeras were bred to identify germline transmission of the Erbb3f allele. 
Subsequent generations of isogenic mice carrying the Erbb3f allele were 
maintained on the 129S6/SvEvTAC background. Genotypes of individual 
mice were determined by PCR with mErbb3-S1 and mErbb3-AS1 primers.
Mice and crosses. Cre transgenic mice, B6;D2-Tg(Vil-Cre)20Syr (Mouse 
Models of Human Cancers Consortium, strain number 01XE7) and 
Tg(Sox2-Cre)1Amc/J, were obtained from NCI-Frederick and The Jackson 
Laboratory, respectively, and maintained on a B6 background. B6-ApcMin 
mice were obtained from The Jackson Laboratory. Erbb3f/– mice were 
crossed to Cre transgenic lines to get Erbb3+/–CreTg or Erbb3f/+CreTg mice. 
These mice were further backcrossed to Erbb3+/– or Erbb3f/+ mice to get 
conditionally targeted Erbb3 mice (Erbb3f/–CreTg or Erbb3f/fCreTg). Although 
most experiments used Erbb3f/– rather than Erbb3f/f mice to enhance the 
likelihood of generating cells efficient for ERBB3 upon Cre-mediated 
excision, no detectable differences were observed between Erbb3f/f and 
Erbb3f/– mice. All controls were littermates of various genotypes with nor-
mal ERBB3 levels. The genotype of each mouse was determined by PCR 
using mErbb3-S1 and mErbb3-AS1; these primers give a 354-bp product 
for the wild-type Erbb3 allele, a 235-bp product for the Erbb3– null allele, a 
488-bp product for the Erbb3f conditional allele, and 193-bp PCR product 
specific for the Erbb3fd Cre-deleted allele. Cre transgenic mice were iden-
tified using PCR with cre-S1, 5′-GTGATGAGGTTCGCAAGAAC-3′ and 
cre-AS1, 5′-AGCATTGCTGTCACTTGGTC-3′ primers, which produces a 
278-bp PCR product. Mice were genotyped for the ApcMin allele as previously 
described (33). Mice were fed Purina Mills Lab Diet 5058 under specific 
pathogen–free conditions in an American Association for the Accredita-
tion of Lab Animal Care–approved facility. Mice were euthanized by CO2 
asphyxiation for tissue collection.
Approval of animal experiments. All experiments involving mice were 
reviewed and approved by the Institutional Animal Care and Use Commit-
tee of the University of North Carolina, Chapel Hill.
BrdU and TUNEL staining. Tissues were labeled with BrdU (Sigma-Aldrich) 
for 2 hours after intraperitoneal injection with 10 mM BrdU in PBS, 
pH 7.4, at 0.1 ml/10 g body weight. Small intestines and colons were fixed 
in 10% neutral buffered formalin (NBF) and embedded with paraffin. 
Paraffin sections (7 μm) were immunostained with a BrdU staining kit 
(Zymed, Invitrogen) or with a TUNEL staining kit (Chemicon) according 
to manufacturer’s protocols.
DSS treatment and histological scoring. DSS (36–50 kDa; MP Biomedicals) 
was dissolved in deionized water at 1.5% (w/v) and administered to mice ad 
libitum in drinking water. The body weight of each mouse was measured 
daily. The colon was excised at 8 days after treatment, fixed in 10% NBF, 
and embedded with paraffin. Paraffin sections (7 μm) were stained with 
H&E for histological analysis. The severity of mucosal injury was graded on 
a scale of 0 to 3 as previously described, with minor modifications: grade 
0, normal; grade 1, partial destruction of crypts; grade 2, complete loss of 
crypts; and grade 3, complete loss of crypts and epithelial cells (43). The 
histological score was determined by multiplying the portion of injured 
surface by the grade of severity. Three different regions of distal colon were 
used for histological scoring, and the histological scores from individual 
mice were determined by adding all 3 values. Histological scoring was per-
formed in a blinded fashion.
Macroadenoma counts. The small intestine and colon were removed from 
each mouse. The small intestine was cut into thirds, and each segment 
gently flushed with PBS to remove fecal material, cut longitudinally, and 
splayed flat. Tumor numbers and diameters were obtained for all tumors 
with a dissecting microscope and in-scope micrometer. The smallest 
tumors that can be counted are approximately 0.3 mm in diameter. Tumor 
scoring was performed by a researcher blinded to genotype. Tumor loca-
tion along the gastrointestinal tract was also recorded.
Histology and immunohistochemistry. Intestinal tissues or colon samples 
were rolled into a jelly roll before being fixed in 10% NBF. The processed 
tissues were embedded in paraffin and sectioned (7 μm). Every 50 μm, sec-
tions were taken and stained with H&E. Immunohistochemical procedures 
Figure 8
Model of ERBB interactions in colon cancer growth. Data suggest that 
2 ERBB-mediated pathways support colon cancer growth. An EGFR-
ERBB3-mediated pathway is proposed to be required for tumorigen-
esis, while an independent ERBB3-mediated pathway is proposed to 
support cell survival by preventing apoptosis.
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were performed as described previously (44). Intestinal tumors were rap-
idly dissected, fixed in 10% NBF, and embedded in paraffin before being 
cut in 7-μm-thick sections. For immunohistology, antigen retrieval was 
performed by boiling for 20 minutes in citrate buffer, pH 6.0. Sections 
were treated with 0.3% hydrogen peroxide in PBS for 30 minutes, washed 
in PBS, blocked in PBS plus 3% goat serum and 0.1% Triton X-100, and 
then incubated with primary antibodies and HRP-conjugated goat anti-
rabbit secondary antibody (Sigma-Aldrich). Antigen-antibody complexes 
were detected with DAB peroxidase substrate kit (Vector Laboratories) 
according to the manufacturer’s protocol. For immunofluorescence of 
CTNNB1, antigen retrieval was performed by boiling for 20 minutes in 
citrate buffer, pH 6.0. Sections were blocked with 5% normal donkey serum 
for 45 minutes at room temperature, followed by primary and secondary 
antibodies (each for 1 hour; 1:200 in blocking buffer) at room tempera-
ture. Sections were counterstained with DAPI and visualized with standard 
fluorescence microscopy. The primary antibodies used were anti-CTNNB1 
(sc-7199; Santa Cruz Biotechnology Inc.), anti–Ki-67 (Neomarker), and 
rabbit polyclonal phospho–RPS6 (Ser235/236) antibody (2211; Cell 
Signaling Technology). For immunofluorescence of ERBB3 and CDH1, 
4-μm paraffin sections were baked at 60°C for 30 minutes and then cooled 
to ambient temperature. Sections were sequentially incubated in xylene 
(5 minutes twice), 100% ethyl alcohol (5 minutes twice), 95% ethyl alco-
hol (5 minutes twice), and 80% ethyl alcohol (5 minutes). After washing 
with water, the sections were antigen retrieved using citrate buffer (pH 6.0; 
Dako) in a steamer for 25 minutes and cooled 20 minutes at room tem-
perature. Sections were washed with TBS Tween-2 (TBS-T; 10 mM Tris-
HCl [pH 7.4], 150 mM NaCl, 0.05% Tween-20), quenched with 3% hydro-
gen peroxide in TBS for 10 minutes, blocked for avidin/biotin reactivity 
(00-4303; Zymed, Invitrogen), and blocked with serum-free protein block-
ing reagent (Invitrogen) for 1 hour at room temperature. Subsequently, the 
slides were incubated with anti-ERBB3 (sc-285) and anti-CDH1 (sc-7870; 
both Santa Cruz Biotechnology Inc.) antibodies at 4°C overnight. The 
immunofluorescence was developed using TSA kits 25 and 22 (Invitrogen) 
based on the manufacturer’s instructions. Adjacent slides were stained 
with DAPI to visualize nuclei.
Western blot analysis. The jejunum and colon were dissected from 
3-month-old mice, cut longitudinally, and washed thoroughly with cold 
PBS to remove fecal material before being splayed flat on Parafilm. The 
epithelial layer was harvested by gently scraping the surface with a razor 
blade, frozen in liquid nitrogen, and stored at –80°C. For collection of 
tumors, each tumor was microdissected with sharp forceps under a dissect-
ing microscope, frozen in liquid nitrogen, and stored at –80°C. An extract 
of harvested tissues was prepared by homogenization in buffer (20 mM 
HEPES [pH 7.4], 150 mM NaCl, 2 mM EDTA, 2 mM EGTA, 0.1% Triton 
X-100, 10% glycerol, 1 mM phenylmethylsulfonyl fluoride, 1 μg/ml leu-
peptin, 1 μg/ml aprotinin). The concentration of cleared lysate was mea-
sured by the Bradford assay (Bio-Rad), and 14 μg (epithelial scraping) or 
2 μg (microadenomas) of protein lysate was loaded onto a 6%–14% acryl-
amide gel depending on target protein, electrophoresed, and transferred to 
a PVDF membrane (Bio-Rad). The membrane was incubated in blocking 
solution containing 5% nonfat dried milk or 1% BSA in TBS-T for 1 hour 
at room temperature and subsequently incubated with primary antibody 
in TBS-T at 4°C overnight. After incubation with primary antibody, the 
membrane was washed 4 times in TBS-T and then incubated in blocking 
solution containing goat anti-rabbit immunoglobulin conjugated with 
HRP for 1 hour at room temperature. The membrane was further washed 
4 times in TBS-T, and specific protein complexes were visualized with the 
ECL system or ECL Plus (GE Healthcare). The antibodies used were: EGFR 
(Maine Biotechnology Services or Lab Vision); ERBB2, ERBB3, ERBB4 
(Santa Cruz Biotechnology Inc.); MAPK1/MAPK3, phospho-MAPK1/
MAPK3 (Cell Signaling Technology); AKT, phospho-AKT (Ser473; Cell 
Signaling Technology); CASP3 (Cell Signaling Technology); PARP (Cell 
Signaling Technology); phospho-PDK1 (Ser241; BD Biosciences); RPS6, 
phospho-RPS6 (Ser235/236; Cell Signaling Technology); ACTB (Sigma-
Aldrich). Relative intensities of each signal were quantified by scanning 
X-ray films using LAS 3000 (Fujifilm) and performing densitometry.
Cell culture and siRNA transfection. HCT116 colon cancer cells were main-
tained in McCoy’s 5A medium supplemented with 10% FBS (Invitrogen) 
at 37°C in a humidified atmosphere of 5% CO2. One day before transfec-
tion, 5 × 103 cells were passed to 96-well plates, 1 × 105 cells onto coverslips 
in 35-mm dishes, or 2 × 105 cells to 6-well plates, and 20 nM of a Stealth 
siRNA duplex oligonucleotide (Invitrogen) was delivered into cells using 
Lipofectamine RNAiMAX reagent (Invitrogen). The sense sequences for 
siRNA duplex were ERBB3-siRNA1, 5′-GGCCAUGAAUGAAUUCUCUA-
CUCUA-3′; ERBB3-siRNA3, 5′-CAAUACCAGACACUGUACAAGCUCU-3′; 
ERBB4-siRNA1, 5′-GAAAUCAGCGCAGGAAACAUCUAUA-3′; and 
ERBB4-siRNA2, 5′-CCAUCCAGCUGGUUACUCAACUUAU-3′. Two 
negative controls were used that consisted of transfection reagent only or 
scrambled duplex with average GC content (Invitrogen). The medium was 
changed at 1 and 3 days after transfection for cell proliferation assays or 
1 day after transfection for TUNEL assays and cell harvesting.
Cell proliferation and TUNEL assays and preparation of cell extracts. Four days 
after siRNA transfection, cell proliferation was quantified using a colorimet-
ric assay based on the cleavage of the tetrazolium salt WST-1 by mitochon-
drial dehydrogenases in viable cells (Daeillab). Ninety-six-well plates were 
incubated at 37°C for 1 hour, and the absorbance was determined at 450 
nm on a plate reader (Molecular Devices). Apoptotic cells were quantified 
with the ApopTag fluorescein in situ apoptosis detection kit (Chemicon, 
Millipore) according to the manufacturer’s protocol and counterstained 
with DAPI. Cell extracts were prepared by scraping the cells of 6-well plates 
with homogenation buffer as described above for the mouse tissues.
Statistics. Unpaired Student’s t test was used to analyze histological scores 
and densitometry measurements. DSS-induced body weight loss was ana-
lyzed by using the Mann-Whitney U test. The nonparametric Wilcoxon 
rank-sum test was used to analyze tumor counts and Student’s t test for 
the number of Ki-67– and TUNEL-positive cells. Statistical analysis was 
performed with StatView (SAS Institute). One-sided P values are given, and 
values less than 0.05 were considered significant.
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